Compare AU

Compare CURE vs. EMMG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and EMMG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

CURE

EMMG

Popularity

Low

Low

Pearlers invested

82

5

Median incremental investment

$619.50

$1,997.66

Median investment frequency

Monthly

Monthly

Median total investment

$1,323.41

$2,086.50

Average age group

> 35

> 35


Key Summary

CURE

EMMG

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

EMMG.AX was created on 2019-05-29 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to generate after-fee returns in excess of the MSCI Emerging Markets Index expressed in Australian Dollars over rolling five-year periods. The Fund invests in a portfolio of emerging market shares that is actively managed by Legg Masons wholly-owned equity specialist, Martin Currie

Top 3 holdings

Natera Inc (3.41 %)

Incyte Corp (2.94 %)

Gilead Sciences Inc (2.88 %)

BetaShares Martin Currie Em Fund (Managed Fund) (100 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

China (20.90 %)

India (20.69 %)

Korea (17.98 %)

Management fee

0.45 %

1 %


Key Summary

CURE

EMMG

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

1 %

Price

$49.94

$6.50

Size

$38.065 million

$15.591 million

10Y return

N/A

N/A

Annual distribution/โ€Šdividend yield (5Y)

4.24 %

0.56 %

Market

ASX

ASX

First listed date

12/11/2018

06/06/2019

Purchase fee

$6.50

$6.50


Community Stats

CURE

EMMG

Popularity

Low

Low

Pearlers invested

82

5

Median incremental investment

$619.50

$1,997.66

Median investment frequency

Monthly

Monthly

Median total investment

$1,323.41

$2,086.50

Average age group

> 35

> 35


Pros and Cons

CURE

EMMG

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

EMMG

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home